Nothing Special   »   [go: up one dir, main page]

CN1186447A - 沙美特罗的计定剂量吸入器 - Google Patents

沙美特罗的计定剂量吸入器 Download PDF

Info

Publication number
CN1186447A
CN1186447A CN96194410A CN96194410A CN1186447A CN 1186447 A CN1186447 A CN 1186447A CN 96194410 A CN96194410 A CN 96194410A CN 96194410 A CN96194410 A CN 96194410A CN 1186447 A CN1186447 A CN 1186447A
Authority
CN
China
Prior art keywords
inhaler
fluorohydrocarbon
pharmaceutical preparation
salmeterol
high polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96194410A
Other languages
English (en)
Other versions
CN1142798C (zh
Inventor
I·C·阿舒尔斯特
C·S·赫尔曼
L·利－博韦
M·T·里伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27025573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1186447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of CN1186447A publication Critical patent/CN1186447A/zh
Application granted granted Critical
Publication of CN1142798C publication Critical patent/CN1142798C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/44—Valves specially adapted therefor; Regulating devices
    • B65D83/52—Valves specially adapted therefor; Regulating devices for metering
    • B65D83/54—Metering valves ; Metering valve assemblies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0222—Materials for reducing friction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

计量剂量吸入器,该吸入器的内表面由一种或多种氟烃高聚物涂衬,随意与一种或多种非氟烃高聚体组合,用于分散吸入药物制剂,该药物制剂包含Sakmeterol或它的生理上可以接受的盐和氟烃抛射剂基质,随意与一种或多种其它药理活性剂和一种或多种赋型剂组合。

Description

沙美特罗的计定剂量吸入器
发明背景
治疗呼吸道和鼻腔疾患的药物常常以气溶胶制剂由口腔或鼻腔给药。配制这类气溶胶药物制剂的一种广泛应用的方法包括制作药物的悬浮制剂，将药物以分散很好的粉末悬浮在称为抛射剂基质的液化气体中。该悬浮剂储存在封口容器里，该封口容器可以耐受保持抛射剂为液态所需的压力。当安装在容器上的剂量计量阀被触发时，悬浮剂即喷出。
设计剂量阀时是使阀每次触发时一致地释放出固定的、预先确定量的药物制剂。由于悬浮剂经过剂量计量阀通过抛射剂的蒸气高压由容器受力，抛射剂迅速蒸发而留下药物制剂的极细小颗粒的快速运动的云状物。通过渠道形成装置，例如通过园筒或开口的锥形该颗粒云状物射向病人的鼻或口。与气溶胶剂量计量阀触发的同时，病人将药物颗粒吸入肺或鼻腔。按这种方式喷雾药物的系统称为“计定剂量吸入器”(MDI′s)。Peter Byron，Respiratory Drug Delivery，CRCPress，Boca Raton，FL(1990)描述了这种形式治疗的一般背景。
病人常常依赖于MDI′s释放的药物迅速治疗可使人体虚弱，在有些情况下甚至可以危及生命的呼吸道疾病。所以释放给病人的气溶胶药物制剂剂量必须始终满足制药公司声明的规格要求以及必须遵守FDA和别的管理机构的规定。也就是说，罐中的每次剂量在接近的公差范围内必须相同。
一些气溶胶药物趋向于粘附在内表面上，即粘附在MDI的罐阀和帽壁上。这可导致每次触发MDI时病人获得的药量明显少于处方规定的药量。这个问题对于氢氟烷(亦简称“氟烃”)抛射剂基质系统，例如P134a和P227尤其尖锐，该系统是近年开发用于取代氯氟烃例如P11、P114和P12的。
我们发现用氟烃高聚物涂衬MDI′s罐的内部表面，显著减少或基本消除沙美特罗(Salmeterol)粘附或沉淀在容器壁上的问题从而保证气溶胶中的药物从MDI始终如一地释放。
                 本发明的概述
内表面部分或全部用一种或多种氟烃高聚物作衬的计定剂量吸入器，该高聚物随意与一种或多种非氟烃高聚物组合，该计量剂量吸入器用于喷雾吸入药物制剂，该制剂含Salmeterol或它的生理上可以接受的盐及氟烃抛射剂基质，并随意地与一种或多种其它药理活性物质或一种或多种赋型剂联用。
                    本发明的详述
术语“计量剂量吸入器”或“MDI”是指一种由一个罐、盖隹罐口的缩边帽和安装在帽上的药物计量阀组成的装置，而术语“MDI系统”还包括适当渠道形成装置。术语“MDI罐”指无帽和无阀的罐。术语“药物计量阀“或”MDI阀”指MDI阀每次触发时从中释放预先决定量药物制剂的阀及它的有关机械。渠道形成装置可以包括例如阀驱动器和园筒或锥样通道，药物可经过该装置从填充的MDI罐经MDI阀释放到病人的鼻或口中，例如唇状驱动器。美国专利5,261,538中描述了典型的MDI部件的关联，该专利这里列为参考文献。
术语“氟烃高聚物”指烃链中一个或多个氢原子被氟原子取代的高聚物。这样，“氟烃高聚物”包括全氟烃-、氢氟烃-、氯氟烃-、氢氯氟烃高聚物或它们的其它卤素取代的衍生物。这类“氟烃高聚物”可以是支链的、均聚物或共聚物。
美国专利No.4,992,474发明了一组支气管扩张化合物，该化合物对于治疗气喘和其它呼吸道疾病特别有用，该化合物的化学名为4-羟基-α1-〔〔〔6-(4-苯基丁氧)己基〕氨基〕甲基〕-1，3-苯二甲醇，普通名为Salmeterol。Salmeterol以游离碱如酸的加合盐(特别是作为1-羟基-2-萘羧酸的盐，亦称羟萘酸盐或Xinafoate盐)特别是以气溶胶的形式已经被医药社会广泛接受为有用的气喘治疗药并以“Serevent”的商标上市。
术语“药物制剂”指Salmeterol或它的生理上可以接受的盐(特别是羟萘酸盐)随意与一种或多种其它药理活性剂例如抗炎剂，镇痛剂或其它呼吸道药物联合，并随意含一种或多种赋形剂。这里使用的术语“赋型剂”指有小的药理活性或根本没有药理活性(对用量而言)但可加强药物制剂或完善MDI系统的效能。例如，赋型剂包括表面活性剂，防腐剂、芳香剂、抗氧化剂、抗凝聚剂和助溶剂，例如乙醇和乙醚，但不限于这些。Salmeterol或它的盐可以使用R异构体。
适宜的表面活性剂为文献已知，例如欧洲专利申请No，0327777中发明的那些表面活性剂。表面活性剂的理想用量范围为相对于药物重量的0.0001％至50％，特别为0.05％至5％。特别有用的表面活性剂为1，2-二〔7-(F-己基)己酰基〕-甘油基-3-磷-N，N，N-三甲基乙醇胺，亦称为3，5，9-三氧杂-4-磷杂二十二碳-1-铵，17，17，18，18，19，19，20，20，21，21，22，22，22-十三氟-7-〔(8，8，9，9，10，10，11，11，12，12，13，13，13-十三氟-1-氧代十三烷基)氧基〕-4-羟基-N，N，N-三甲基-10-氧代-，内盐，4-氧化物。
该药物制剂中能够包括的极性助溶剂有C2-6的脂肪醇和多元醇，例如乙醇、异丙醇和丙二醇，乙醇为优选，这类助溶剂按期待的量使用，或作为唯一的赋型剂使用，或再加上其它赋型剂，例如加上表面活性剂。适当地，该药物制剂可以含极性助溶剂例如含乙醇的量可占抛射剂基质重量的0.01％至5％，优选含0.1％至5％，例如含大约0.1％至1％。
技术人员应当认识到，希望的话本发明中使用的药物制剂可以含Salmeterol或它的盐与一种或多种其它药理活性剂的组合。这类药物可以选自吸入治疗中适宜的任何药物。例如合适的药物可选自镇痛药，例如可待因，二氢吗啡，麦角胺、芬太尼或吗啡；咽类制品，例如diltiazem；抗过敏药，例如色甘酸酯、Ketotifen或nedocromil；抗感染药，例如头孢菌素、青霉素、链霉素、磺胺、四环素和戊烷脒；抗组胺药，例如麦沙非林；抗炎药，例如氯地米松(例如它的二丙酸盐、flunisolide、budesonide、tipredane或去炎松；镇咳药，例如诺斯卡品；支气管扩张剂，例如舒喘灵、麻黄素、肾上腺素、芬成醇、formoterol、异丙肾上腺素、二羟苯基异丙氨基乙醇、脱羟肾上腺素、去甲麻黄碱、pirbuterol、reproterol、羟哌甲苯二酚、间羟叔丁肾上腺素、新异丙肾上腺素、tulobuterol、间羟异丙肾上腺素、或(-)-4-氨基-3，5-二氯-α-〔〔〔6-〔2-(2-吡啶基)乙氧基〕己基〕氨基〕甲基〕苯甲醇；利尿药，例如氨氯吡啶脒；抗胆碱能药，例如ipratropiun、阿托品或oxitropium；激素，例如可的松、氢化可的松或盘的松龙；黄嘌呤，例如氨荼碱、胆碱荼碱、赖氨酸荼碱、或荼碱；以及治疗用的蛋白和多肽，例如胰岛素或胰高血糖素。技术人员应当明确，适当时这些药物可以以盐的形式使用(例如以碱金属盐、铵盐或酸加合盐的形式使用)，或以酯的形式使用(例如以低级烷基酯的形式使用)，或以溶剂化物的形式使用(例如以水合物的形式使用)，以便优化药物的活性和/或稳定性和/或降低药物在抛射剂基质中的溶解度。
特别优选的药物制剂含Salmeterol或它的生理上可以接受的盐与一种抗炎甾体，例如与丙酸fluticasone或二丙酸氯地米松或它们的生理上可以接受的溶剂化物组合。
特别优选的药物组合是硫酸Salmeterol Xinafonate和二丙酸fluticason。
这里使用的“抛射剂基质”是指沸点为大约室温(25℃)至大约-25℃的生理惰性液体，室温下该惰性液体单独或以组合的方式产生高蒸气压。MDI系统触发时，MDI中的抛射剂基质的高蒸气压先通过计量阀往外推动计量的药物制剂，然后抛射剂基质迅速蒸发分散药物颗粒。本发明中使用的抛射剂基质为低沸点氟烃；特别是1，1，1，2-四氟乙烷，亦称为“抛射剂基质134a”或“P134a”和1，1，1，2，3，3，3-七氟丙烷，亦称为“抛射剂基质227”或“P227”。
本发明中使用的药物制剂可以不含或基本不含制剂赋型剂，例如不含表面活性剂和助溶剂等。这类药物制剂由于本质上是无味和无臭的，比起含赋型剂的制剂来刺激性和毒性都小，所以是有利的制剂。这样，一种优选的药物制剂主要由Salmeterol或它的生理上可以接受的盐例如Xinafoate盐组成，随意与一种或多种其它药理活性剂特别是与丙酸fluticason或它的生理上可以接受的溶剂化物以及氟烃抛射剂基质组合。优选的抛射剂基质为1，1，1，2-四氟乙烷、1，1，1，2，3，3，3-七氟正丙烷或它们的混合物，1，1，1，2-四氟乙烷特别优选。
本发明中使用的进一步的药物制剂可以不含或基本不含表面活性剂。这样，进一步优选的药物制剂，包括或主要由舒喘宁(或它的生理上可以接受的盐)组成，随意与一种或多种其它药理活性剂、一种氟烃抛射剂基质，以及占抛射剂基质重量0.01％至5％的极性助溶剂组合，该制剂本质上不含表面活性剂。优选的抛射剂基质为1，1，1，2-四氟乙烷、1，1，1，2，3，3，3-七氟正丙烷或它们的混合物，特别优选为1，1，1，2-四氟乙烷、或1，1，1，2，3，3，3-七氟正丙烷。
虽然其它不受药物制剂影响的金属，例如不锈钢、铜的合金或锡板都可以使用，但MDI罐和盖最常用铝或铝合金制作。MDI罐亦可用玻璃或塑料制作。不过本发明中MDI罐优选用铝或它的合金制造。有利地可以使用强化铝或铝合金MDI罐。这类强化的MDI罐能够耐受特别高压的加衬和加工处理条件，例如耐受特别的高温，这类条件对一些氟烃高聚物可能是必须的。高温下具有降低变形趋势的加强的MDI罐包括由侧壁和增厚底组成的MDI罐和由本质椭园形底(该形状底增大了侧壁和罐底的角度)构成的MDI罐，而不是标准MDI罐的半球底，具有椭园底的MDI罐为进行加衬工艺提供了进一步的好处。
药物计量阀的构件通常由不锈钢和药理上是惰性并耐气雾剂基质的高聚物构成，这类高聚物有缩醛，聚酰胺(例如尼龙)：聚碳酸酯，聚酯、氟烃高聚物(例如聚四氟乙烯)或这些物料的组合物。另外各种物料(例如氰橡胶、聚脲烷、乙酰树脂、氟烃高聚物)的封条和“0”环，或其它弹性物料都可用于阀内或四周。
本发明中使用的氟烃高聚物体包括由一个或多个下述单体单元的多重复合构成的氟烃：四氟乙烯(PTFE)、氟化的乙烯丙烯(FEP)。全氟烷氧基烷(PFA)、乙烯四氟乙烯(ETFE)、乙烯二烯氟化物(PVDF)，和氯化的乙烯四氟乙烯。具有相对高氟/碳比的氟化高聚物例如全氟烷高聚物PTFE、PFA和FEP为优选。
氟化高聚物可以与非氟高聚物掺合，例如与聚酰胺、聚酰亚胺、聚醚砜、对聚苯硫和胺醛热固树脂掺合。加这些高聚物可改善高聚物衬与罐壁的粘着性能。优选的高聚掺合物为PTFE/FEP/聚酰胺酰亚胺、PTFE/聚醚砜(PES)和FEP-苯并胍胺。
特别优选的衬(涂层)为纯PFA，FEP和PTFE和聚醚砜(PES)的掺合物。
市场销售的氟烃高聚物的商标为聚四氟乙烯、Tefzel、Halar和Hostaflon、Polyflon和Neoflon。高聚物的级别包括FEP杜邦856-200、PFA杜邦857-200、PTFE-PES杜邦3200-100、PTFE-FEP-聚酰胺酰亚胺杜邦856P23485、FEP粉杜邦532和PFA Hoechst6900n。衬厚度的范围为大约1μm至大约1mm。适宜的衬厚度范围为大约1μm至大约100μm，例如1μm至25μm。可以使用一层或多层衬。
优选地本发明中使用的氟烃高聚物衬到金属制作的MDI罐上，特别是衬到铝或铝合金制作的MDI罐上。
特殊的(例如粉碎的)药物的粒度应为在施用气溶胶制剂时允许将基本上所有的药物吸入肺部，因此应小于100微米，理想情况下小于20微米，特别是在1至10微米范围内，例如在1至5微米范围内。
理想情况下气溶胶制剂的药物与制剂总重量的相对比例为0.005％至10％，尤其为0.005％至5％，特别为0.01％至1.0％。
本发明的进一步的方面是计定剂量的吸入器，该吸入器金属内表面部分或全部用一种或多种氟烷高聚体涂衬，随意与一种或多种非氟烷高聚体合用，用于分散由Salmeterol或它的盐类和氟烃抛射剂基质，并随意与一种或多种其它药理活性剂以及一种或多种赋形剂组合的药物制剂。
本发明的特别方面是全部内部金属表面基本都由PFA或FEP，或掺合的氟高聚体树脂系统例如PTFE-PES加衬的MDI，该MDI可有或可无聚酰胺酰亚胺或聚醚砜底衬，用于分散上面定义的药物制剂。
本MDI中使用的优选药物制剂主要含Salmeterol(或它的生理上可以接受的盐，例如Xinafoate盐)，随意与一种或多种药理活性剂特别是与丙酸luticasone或它的生理上可以接受的溶剂化物，和氟烃抛射剂基质，尤其是1，1，1，2-四氟乙烷、1，1，1，2，3，3，3-七氟丙烷或它们的混合物，如特别是1，1，1，2-四氟乙烷的组合。优选的MDI罐由铝或铝合金制作。
本MDI可采用文献已知的金属涂衬方法加衬。例如铝或不锈钢一类的金属在冲压和成形为罐状之前可作为卷盘预涂衬并处理。由于两个原因，该方法很适合高容量生产。首先，卷盘涂衬技术很发达，几家制造商常规地涂金属卷盘可以达到高标准的均匀性和广泛的厚度。第二，预涂的卷盘可以高速和高精度冲压和拉伸，使用的方法与未加衬的卷盘基本相同。
得到涂衬罐的其它技术是静电干粉涂衬或先往制好的MDI罐里侧喷氟化高聚物/高聚物掺合物衬的制剂，然后再处理。制好的MDI罐亦可浸到氟烃高聚物/高聚物掺合物衬制剂中并处理，这样在内侧和外侧均形成涂层。该氟烃高聚物/高聚物掺合物制剂亦可倾到MDI罐内，然后排出来，使内侧留下高聚物衬。为容易制作，适宜地将制好的MDI罐用氟烃高聚物/高聚物掺合物喷涂加衬。
氟烃高聚物/高聚物掺合物亦可采用氟烃单体等离子聚合在罐壁就地生成。氟烃高聚膜可吹入MDI罐内侧以便形成袋。各种氟烃高聚物例如ETFE、FEP和PTFE都可用作膜料买到。
适宜的处理温度取决于选择作衬的氟烃高聚物/高聚物掺合物和使用的涂衬方法。不过，对于卷盘和喷涂加衬来说，典型地需要温度高于高聚物熔点，例如比熔点高大约50℃至多20分钟，例如大约5至10分钟，例如8分钟或所需要的时间。对于上面提到的优选或特别优选的氟烃高聚物/高聚物掺合物，处理温度的范围为大约300℃至大约400℃，例如大约350℃至大约380℃为宜。对于等离子聚合可以使用的典型的温度范围为大约20℃至大约100℃。
这里发明的MDI可按文献方法制造(例如见于上面的Byron和美国专利5,345,980)，其中用常规罐代替用氟化高聚物/高聚物掺合物作衬的罐。也就是说Salmeterol或它的盐和制剂的其它组分充入用氟化高聚物/高聚物掺合物涂衬的气溶胶罐中。该罐连有在适当的地方打褶的帽装置。药物在液压氟烃抛射剂基质中的悬浮液可以按美国专利5,345,980(本文引作参考文献)中所示通过计量阀引起罐内。
这里发明的内部用氟烃高聚物/高聚物掺合物涂衬的MDI可采用与目前临床用的无衬MDI′S类似的方式用于医疗。不过本发明的MDI′S对于含有和喷施含有氢氟烷氟烃抛射剂基质例如134a和少含或基本不含赋形剂、以及倾向于沉淀或粘着到MDI系统的内壁和部件的药物制剂特别有用。有些情况下调配基本不含赋形剂的吸入药物是有利的，例如当病人对赋型剂过敏或药物与赋形剂反应时就是如此。
含上面描述的制剂的MDI、MDI系统和用这类MDI系统治疗呼吸道疾病，例如治疗哮喘包括本发明的进一步的方面。
对于本领域技术人员来说，修饰这里描述的发明可以在不偏离本发明的精神下容易做到是明确的。寻求的对这里描述的一切题材保护中也包括任何这类修饰。
下面的非限制性实施例解释本发明。
                 实施例
                 实施例1
标准的12.5ml  MDI罐(Presspart Inc，Cary，NC)先喷涂衬以(Livingstone Coatings，Charlotte，NC)底漆(杜邦851-204)和按照卖主的标准方法处理，然后再喷涂衬以FEP或PFA(分别为杜邦856-200和857-200)，并按照卖主的标准方法处理。涂层的厚度为大约10mm至50mm。这些罐然后清除空气(见于PCT申请号WO94/22722PCT/EP94/00921)，阀门弯边定位，通过阀门往里充大约4mg Salmeterolxinafoate(羟萘酸盐)和大约12g P134a的悬浮液。
                   实施例2
标准的0.46mm厚的铝片(United Aluminum)喷涂衬以(杜邦，Wilmington，DE)FEP(杜邦856-200)并处理。该片然后深拉成罐(Presspart Inc，Cary，NC)。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约2.5mg Salmeterol xinafoate(羟萘酸盐)与大约7.5gP134A的悬浮液。
                 实施例3
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)啧涂衬以PTFE-PES掺合物(杜邦)为单一衬，并按卖主的标准方法处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.1mg微粉化的Salmeterol xinafoate与大约12gP134a的悬浮液。
                   实施例4
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)啧涂衬以PTFE-FEP-聚酰胺酰亚胺掺合物(杜邦)并按卖主的标准方法处理。涂层的厚度在大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.1mg微粉化的Salmeterol xinafoate与大约12gP134a的悬浮液。
                    实施例5
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)用静电枪喷涂衬以FEP粉(杜邦FEP532)。涂层的厚度在大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.1mg微粉化的Salmeterol xinafoate与大约12gP134a的悬浮液。
                    实施例6
标准的0.46mm厚的铝片(United Aluminum)喷涂衬以FEP-苯并胍胺并处理。该铝片然后深拉成罐。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.1mg微粉化的Salmeterol  xinafoate与大约12gP134a的悬浮液。
                    实施例7
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PFA的水性分散液(Hoechst PFA-6900n)并处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.1mg微粉化的Salmeterol xinafoate与大约12gP134a的悬浮液。
                        实施例8
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-PES掺合物(杜邦)为单一衬，并按卖主的标准方法处理。涂层的厚度在大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充4.25mg微粉化的Salmeterol xinafoate与大约8gP134a的悬浮液。
                      实施例9
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-FEP-聚酰胺酰亚胺掺合物(杜邦)并按卖主的标准方法处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4.25mg微粉化的Salmeterol xinafoate与大约8gP134a的悬浮液。
                   实施例10
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)用静电枪喷涂衬以FEP粉(杜邦FEP532)。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4.25mg微粉化的Salmeterol xinafoate与大约8gP134a的悬浮液。
                    实施例11
标准的0.46mm厚的铝片(United Aluminum)喷涂衬以FEP-苯并胍胺并处理。该铝片然后深拉成罐。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4.25mg微粉化的Salmeterol xinafoate与大约8gP134a的悬浮液。
                    实施例12
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PFA的水性分散液(Hoechst PFA-6900n)并处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4.25mg微粉化的Salmeterol  xinafoate与大约8gP134a的悬浮液。
                    实施例13
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-PES掺合物(杜邦)为单一衬，并按卖主的标准方法处理。涂层的厚度在大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.4mg微粉化的Salmeterol xinafoate与大约8.8mg、22mg或44mg微粉化的丙酸fluticasone与大约12g P134a的悬浮液。
                    实施例14
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-FEP-聚酰胺酰亚胺掺合物(杜邦)并按卖主的标准方法处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.4mg微粉化的Salmeterol xinafoate与大约8.8mg、22mg或44mg微粉化的丙酸fluticasone与大约12g P134a的悬浮液。
               实施例15
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)用静电枪喷涂衬以FEP粉(杜邦FEP532)。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.4mg微粉化的Salmeterol xinafoate与大约8.8mg、22mg或44mg微粉化的丙酸fluticasone与大约12g P134a的悬浮液。
                    实施例16
标准的0.46mm厚的铝片(United Aluminum)喷涂衬以FEP-苯并胍胺并处理。该铝片然后深拉成罐。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.4mg微粉化的Salmeterol xinafoate与大约8.8mg、22mg或44mg微粉化的丙酸fluticasone与大约12g P134a的悬浮液。
                 实施例17
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PFA的水性分散液(Hoechst PFA-6900n)并处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约6.4mg微粉化的Salmeterol xinafoate与大约8.8mg、22mg或44mg微粉化的丙酸fluticasone与大约12g P134a的悬浮液。
                   实施例18
标准的12.5ml  MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-PES掺合物(杜邦)为单一衬，并按卖主的标准方法处理。涂层的厚度在大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4mg微粉化的Salmeterol xinafoate与大约5.5mg、13.8mg或27.5mg丙酸fluticasone与大约8g P134a的悬浮液。
                    实施例19
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PTFE-FEP-聚酰胺酰亚胺掺合物(杜邦)并按卖主的标准方法处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4mg微粉化的Salmeterol xinafoate与大约5.5mg、13.8mg或27.5mg丙酸fluticasone与大约8g P134a的悬浮液。
                  实施例20
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)用静电枪喷涂衬以FEP粉(杜邦FEP532)。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4mg微粉化的Salmeterol xinafoate与大约5.5mg、13.8mg或27.5mg丙酸fluticasone与大约8g P134a的悬浮液。
                  实施例21
标准的0.46mm厚的铝片(United Aluminum)喷涂衬以FEP-苯并胍胺并处理。该铝片然后深拉成罐。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4mg微粉化的Salmeterol  xinafoate与大约5.5mg、13.8mg或27.5mg丙酸fluticasone与大约8g P134a的悬浮液。
                  实施例22
标准的12.5ml MDI罐(Presspart Inc，Cary，NC)喷涂衬以PFA的水性分散液(Hoechst PFA-6900n)并处理。涂层的厚度为大约1μm至大约20μm之间。这些罐然后清除空气，阀门弯边定位，通过阀门往里充大约4mg微粉化的Salmeterol xinafoate与大约5.5mg、13.8mg或27.5mg丙酸fluticasone与大约8g P134a的悬浮液。
                 实施例23至28
重复实施例3至7，不同的是通过阀门往里通大约9.6mg微粉化的Salmeterol  xinafoate与大约21.4g P227的悬浮液。
                 实施例29至33
重复实施例3至7，不同的是通过阀门往里通大约9.6mg微粉化的Salmeterol  xinafoate与大约182mg乙醇及18.2g P134a的悬浮液。
                 实施例34至64
重复实施例3至33，不同的是使用修饰的底本质为椭园的12.5mlMDI罐(Presspart Inc，Cary，NC)。
在模拟使用的条件下测定发现从MDIs释放的药物剂量是恒定的，而对照的充入未衬的罐中的MDIs在应用中显示明显的剂量释放降低。

Claims (22)

1.计定剂量的吸入器，该吸入器的部分或全部内表面涂有一种或多种氟烃高聚体，该氟烃高聚体随意与一种或多种非氟烃高聚体组合，用于喷施含沙美特罗(salmeterol)或它的生理上可以接受的盐及一种氟烃抛射剂基质、并随意与一种或多种其它药理活性剂或一种或多种赋型剂组合的吸入药物制剂。
2.含所述药物制剂的权利要求1的吸入器。
3.权利要求2的吸入器，其中所说的药物制剂进一步包括一种表面活性剂。
4.权利要求2或3的吸入器，其中所说的药物制剂进一步包括一种极性助溶剂。
5.权利要求2的吸入器，其中所说的药物制剂包括占抛射剂基质重量的0.01％至5％的极性助溶剂，该制剂本质上不含表面活性剂。
6.权利要求2至5中任一的吸入器，其中所述的药物制剂含的Salmeterol或它的生理上可以接受的盐与一种甾体抗炎药或抗过敏药组合。
7.权利要求6的吸入器，其中所述的药物制剂含的Salmeterolxinafoate与丙酸fluticasone组合。
8.权利要求2的吸入器，其中所述的药物制剂主要包含Salmeterol或它的生理上可以接受的盐，随意与一种或多种其它药理活性剂及氟烃抛射剂基质组合。
9.权利要求8的吸入器，其中所说的药物制剂主要由Salmeterol或它的生理上可以接受的盐与一种甾体抗炎药或一种抗过敏药组成。
10.权利要求9的吸入器，其中所说的药物制剂主要由Salmeterol或它的生理上可以接受的盐与丙酸fluticasone或它的生理上可以接受的溶剂化物组成。
11.权利要求2的吸入器，其中所说的药物制剂由Salmeterol或它的生理上可以接受的盐和氟烃抛射剂基质组成。
12.权利要求2至11中之任一的吸入器，其中所说的Salmeterol为它的xinafoate盐形式。
13.权利要求2至12中之任一的吸入器，其中氟烃抛射剂基质为1，1，1，2-四氟乙烷或1，1，1，2，3，3，3-七氟正丙烷或它们的混合物。
14.权利要求13的吸入器，其中氟烃抛射剂基质为1，1，1，2-四氟乙烷。
15.权利要求1至14中之任一的吸入器，该吸入器包含一个由金属制作的罐，该罐的内部金属表面一部分或全部涂衬。
16.权利要求15的吸入器，其中的金属为铝或它的合金。
17.权利要求1至16中之任一的吸入器，其中所说的氟烃高聚体为全氟烃高聚体。
18.权利要求17的吸入器，其中所说的氟烃高聚体选自PTFE、PFA、FEP和它们的混合物。
19.权利要求1至18中之任一的吸入器，其中所说的氟烃高聚体与选自聚酰胺酰亚胺和聚醚砜的非氟烃高聚体组合。
20.权利要求1至19中之任一的吸入器，该吸入器含基本为椭园的底。
21.含有权利要求1至20中之任一的计定剂量吸入器的计定剂量吸入器系统，该系统装有用于经口或鼻吸入药物制剂的适合的管道装置。
22.权利要求21的计定剂量吸入系统在治疗呼吸道疾病中的应用。
CNB961944102A 1995-04-14 1996-04-10 沙美特罗的计定剂量吸入器 Expired - Lifetime CN1142798C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42237095A 1995-04-14 1995-04-14
US08/422,370 1995-04-14
US58333296A 1996-01-05 1996-01-05
US08/583,332 1996-01-05

Publications (2)

Publication Number Publication Date
CN1186447A true CN1186447A (zh) 1998-07-01
CN1142798C CN1142798C (zh) 2004-03-24

Family

ID=27025573

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB961944102A Expired - Lifetime CN1142798C (zh) 1995-04-14 1996-04-10 沙美特罗的计定剂量吸入器

Country Status (32)

Country Link
US (2) US6143277A (zh)
EP (4) EP0820323B1 (zh)
JP (1) JPH11509434A (zh)
KR (1) KR100403899B1 (zh)
CN (1) CN1142798C (zh)
AP (1) AP979A (zh)
AT (2) ATE250439T1 (zh)
AU (1) AU718263B2 (zh)
BG (1) BG64117B1 (zh)
BR (1) BR9604977A (zh)
CA (1) CA2217954C (zh)
CY (1) CY2479B1 (zh)
CZ (1) CZ296209B6 (zh)
DE (2) DE69634865D1 (zh)
DK (1) DK0820323T3 (zh)
EA (1) EA000892B1 (zh)
EE (1) EE04005B1 (zh)
ES (1) ES2206572T3 (zh)
HK (1) HK1009405A1 (zh)
HU (1) HUP9802391A3 (zh)
IS (1) IS4579A (zh)
MX (1) MX9707864A (zh)
NO (1) NO974736L (zh)
NZ (1) NZ306280A (zh)
OA (1) OA10626A (zh)
PL (1) PL180901B1 (zh)
PT (1) PT820323E (zh)
RO (1) RO119116B1 (zh)
SK (1) SK284447B6 (zh)
TR (1) TR199701169T1 (zh)
UA (1) UA54386C2 (zh)
WO (1) WO1996032150A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330391C (zh) * 2000-05-23 2007-08-08 葛兰素集团有限公司 供沙美特罗昔萘酸酯制剂用的气雾剂容器
CN102366406A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的沙美特罗替卡松气雾剂制剂
CN106619658A (zh) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 一种医用气溶胶制剂及定量吸入气雾剂

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CN1186473A (zh) * 1995-04-14 1998-07-01 葛兰素惠尔康公司 二丙酸氯地米松计定剂量吸入器
DK0820322T3 (da) * 1995-04-14 2002-10-07 Smithkline Beecham Corp Dosisudmålende inhalator til Fluticason Propionat
WO1996032099A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
EA000892B1 (ru) * 1995-04-14 2000-06-26 Глаксо Веллкам Инк. Дозирующий ингалятор для салметерола
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2332712A (en) * 1997-07-29 1999-06-30 Glaxo Group Ltd Valve for aerosol container
DE19860969B4 (de) * 1997-09-03 2006-03-09 Glaxo Group Ltd., Greenford Dosierventil für einen Druck-Abgabe-Behälter
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
GB9814717D0 (en) * 1998-02-23 1998-09-02 Bespak Plc Improvements in drug delivery devices
ID26130A (id) † 1998-02-23 2000-11-23 Glaxo Group Ltd Penyempurnaan-penyempurnaan dalam alat pengantar obat
GB9805938D0 (en) * 1998-03-19 1998-05-13 Glaxo Group Ltd Valve for aerosol container
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB2340759B (en) * 1998-08-26 2003-05-07 Bespak Plc Improvements in drug delivery devices
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IL150397A0 (en) 2000-01-14 2002-12-01 Astrazeneca Ab A method for applying a polymer coating to the internal surface of a container
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
ATE392885T1 (de) 2000-02-28 2008-05-15 Pharmakodex Ltd Verabreichungssystemen für oral anzuwendende arzneimittel
WO2001064524A2 (en) 2000-03-01 2001-09-07 Glaxo Group Limited Metered dose inhaler
WO2001064274A2 (en) * 2000-03-01 2001-09-07 Glaxo Group Limited Metered dose inhaler
WO2001064275A1 (en) * 2000-03-01 2001-09-07 Glaxo Group Limited Metered dose inhaler
US6971383B2 (en) * 2001-01-24 2005-12-06 University Of North Carolina At Chapel Hill Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
AU2001270074A1 (en) 2000-06-22 2002-01-02 Glaxo Group Limited Method and package for storing a pressurized container containing a drug
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
AU2001289126A1 (en) * 2000-09-18 2002-04-02 Glaxo Group Limited Metered dose inhaler can coated two or more times with fluorocarbon polymers
WO2002030499A2 (en) * 2000-10-13 2002-04-18 Glaxo Group Limited Medicament dispenser
SE0004610D0 (sv) 2000-12-13 2000-12-13 Astrazeneca Ab Surface modification process
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
IL156308A0 (en) * 2000-12-22 2004-01-04 Glaxo Group Ltd Metered dose inhaler for salmeterol xinafoate
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
TR200401980T4 (tr) 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
US20030031806A1 (en) * 2001-07-10 2003-02-13 Jinks Philip A. Medicinal inhalation devices and components coated using thermal chemical vapor deposition
GB0125380D0 (en) * 2001-10-23 2001-12-12 Glaxo Group Ltd Medicament dispenser
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
GB0129397D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US7677411B2 (en) 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
EP1575648A4 (en) * 2002-12-18 2007-07-04 Glaxo Group Ltd DRUG DELIVERY SYSTEM WITH A VENTILATED MOUTHPIECE
WO2004066912A2 (en) * 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
EP1654312B1 (en) 2003-08-11 2014-01-15 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US20080190418A1 (en) 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
JP5618452B2 (ja) 2003-09-16 2014-11-05 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ 呼吸器疾患の治療のためのシクレソニドの使用
WO2005044186A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
EP1686960A4 (en) * 2003-10-28 2007-03-07 Glaxo Group Ltd INHALABLE PHARMACEUTICAL PREPARATIONS EMPLOYING LACTOSE ANHYDRATE, AND METHODS OF ADMINISTERING SAID PREPARATIONS
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
AP2006003734A0 (en) * 2004-03-12 2006-10-31 Cipla Ltd Inhalation formulation
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2569074C (en) 2004-05-31 2012-12-18 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension
AU2006212966B2 (en) 2005-02-10 2008-09-11 DFE Pharma Technology GmbH. Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2006086130A2 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Process for crystallizing lactose particles for use in pharmaceutical formulations
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
GB0721739D0 (en) 2007-11-06 2007-12-19 3M Innovative Properties Co medicinal inhalation devices and components thereof
CA2704985C (en) 2007-11-06 2017-02-28 Philip A. Jinks Medicinal inhalation devices and components thereof
GB0721737D0 (en) 2007-11-06 2007-12-19 3M Innovative Properties Co Medicinal inhalation devices and components thereof
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010129783A1 (en) 2009-05-06 2010-11-11 3M Innovative Properties Company Apparatus and method for plasma treatment of containers
EP2427591A1 (en) 2009-05-06 2012-03-14 3M Innovative Properties Company Medicinal inhalation device
US20120097159A1 (en) 2009-05-06 2012-04-26 Suresh Iyer Medicinal inhalation devices and components thereof
US8541451B2 (en) 2009-07-15 2013-09-24 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
EP4193948A1 (en) 2009-10-27 2023-06-14 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
KR20120109504A (ko) 2009-11-17 2012-10-08 시플라 리미티드 흡입 용액
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
USD666492S1 (en) 2010-11-01 2012-09-04 Colgate-Palmolive Company Cap for a container
USD666098S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666096S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666493S1 (en) 2010-11-01 2012-09-04 Colgate-Palmolive Company Cap for a container
USD666097S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666099S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013024070A1 (en) 2011-08-18 2013-02-21 Nycomed Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2728245T3 (es) * 2012-01-17 2019-10-23 Liconsa Laboratorios Sa Conjunto para administrar medicamentos, e inhalador monodosis para la administrar medicamentos en polvo seco que tiene dicho conjunto
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EA201500651A1 (ru) 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015001561A1 (en) * 2013-07-03 2015-01-08 MEway Pharma LTD Metered dose inhaler and methods thereof
ES2808604T3 (es) * 2014-06-16 2021-03-01 Sanara Tech Ltd Novedoso nebulizador accionado y medios para el mismo
WO2016170009A1 (en) 2015-04-21 2016-10-27 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Ｎｒｆ２路徑的新穎化合物
IL294804A (en) 2020-01-28 2022-09-01 Chiesi Farm Spa Inhalers with a measured dose under pressure containing the composition of pharmacy buffers
CA3165307A1 (en) 2020-02-20 2021-08-26 Enrico Zambelli Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327777A (en) 1885-10-06 Metal-punching machine
US2562118A (en) * 1950-02-09 1951-07-24 Du Pont Polytetrafluoroethylene coating compositions
US2968427A (en) * 1955-06-28 1961-01-17 Meshberg Philip Valve for aerosol container
NL208432A (zh) * 1954-09-20
GB878409A (en) * 1957-03-26 1961-09-27 United Drug And Chemical Compa Improvements in or relating to dispensing devices
US2886217A (en) * 1957-05-20 1959-05-12 Riker Laboratories Inc Dispensing device
US2892576A (en) * 1957-11-14 1959-06-30 Lawrence T Ward Metering button valve assembly
US2980301A (en) * 1958-09-02 1961-04-18 Riker Laboratories Inc Metering valve for aerosol container
GB864392A (en) * 1958-11-10 1961-04-06 Rexall Drug Company Ltd Improvements in or relating to dispensing devices for aerosols
GB1064840A (en) * 1964-11-23 1967-04-12 Du Pont Tetrafluoroethylene/hexafluoropropylene copolymer dispersions
US3506737A (en) * 1965-10-23 1970-04-14 Owens Illinois Inc Glass aerosol bottles and method for making same
US3360158A (en) * 1966-02-16 1967-12-26 American Can Co Container end wall construction
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1191700A (en) 1967-02-27 1970-05-13 Ekco Prod Inc Coated Metalware
FR1584784A (zh) * 1968-08-13 1970-01-02
US3904575A (en) 1969-07-21 1975-09-09 Daikin Ind Ltd Fluorocarbon polymer composition and production and use thereof
FR2082593A5 (en) 1970-03-20 1971-12-10 Oreal Aerosol can prodn
NO134730L (zh) 1971-07-19 1900-01-01
LU63737A1 (zh) 1971-08-17 1972-01-04
US4087026A (en) * 1971-09-15 1978-05-02 Petterson Tor H Barrier package
US3896602A (en) * 1971-09-15 1975-07-29 Tor H Petterson Method of manufacturing of a barrier package
FR2159593A5 (fr) * 1971-11-04 1973-06-22 Skm Sa Installation de peinture par pulverisation
US4143204A (en) * 1971-12-27 1979-03-06 E. I. Du Pont De Nemours And Company Articles coated with fluorocarbon resins
DE2227142A1 (de) * 1972-06-03 1973-12-13 Pampus Kg Rohre und behaelter aus glasfaserverstaerktem kunststoff und einer auskleidung, zum beispiel aus ptfe
US3962171A (en) * 1973-03-02 1976-06-08 Mcgarry & Waters Composition for protecting surfaces
US3929537A (en) * 1973-07-19 1975-12-30 Austral Erwin Engineering Co Preparation of plastic-metal laminates
FR2267496A1 (en) * 1974-04-11 1975-11-07 Sidel Sa Method of sealing valve on aerosol container - uses internally ribbed sleeve over ribbed valve and sleeve
US4180609A (en) * 1975-07-11 1979-12-25 E. I. Du Pont De Nemours And Company Article coated with fluoropolymer finish with improved scratch resistance
BE858111A (fr) 1976-08-26 1978-02-27 Union Carbide Corp Enveloppe de recipient distributeur d'aerosol et son procede de realisation
GB2003415A (en) 1977-09-02 1979-03-14 American Can Co Improvements relating to the manufacture of containers
US4125152A (en) * 1977-09-19 1978-11-14 Borg-Warner Corporation Scale resistant heat transfer surfaces and a method for their preparation
JPS5920547B2 (ja) * 1979-07-04 1984-05-14 東洋製罐株式会社 溶接缶
ZA807387B (en) * 1979-12-08 1981-11-25 Metal Box Co Ltd Containers
JPS56138200A (en) * 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
GB2077229B (en) * 1980-05-16 1983-08-03 Neotechnic Eng Ltd Valve assembly for a pressurized aerosoldispensing container
GB2105189B (en) 1981-07-24 1985-03-20 Fisons Plc Inhalation drugs
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
DE3677811D1 (de) * 1985-04-19 1991-04-11 Nippon Steel Corp Buechse und verfahren zur herstellung von buechsen.
NL8501767A (nl) * 1985-06-19 1987-01-16 Euro Technical Oilservices Bv Inrichting voor het behandelen van een verontreinigingen bevattende vloeistof.
EP0234774B1 (en) * 1986-02-27 1992-05-06 Nippon Kokan Kabushiki Kaisha Precoating metal sheet
JPS6312445A (ja) * 1986-06-24 1988-01-19 東洋製罐株式会社 イ−ジイオ−プン蓋付缶体及びその製法
US4897439A (en) * 1986-07-01 1990-01-30 Edlon Products, Inc. Polymer-metal bonded composite and method of producing same
US5536583A (en) * 1986-07-01 1996-07-16 Edlon Products, Inc. Polymer metal bonded composite and method of producing same
EP0260084B1 (en) * 1986-09-08 1992-12-30 Asia Can Company Limited Metal container and method of manufacturing the same
US4819834A (en) * 1986-09-09 1989-04-11 Minnesota Mining And Manufacturing Company Apparatus and methods for delivering a predetermined amount of a pressurized fluid
EP0327777A1 (fr) 1988-02-12 1989-08-16 S.A. DES ETABLISSEMENTS STAUBLI (France) Capteur de déplacement pour machines automatiques
GB2205297B (en) * 1987-06-05 1991-06-19 Lin Pac Mouldings A container assembly
JPS649158A (en) * 1987-06-22 1989-01-12 Takeuchi Press Metal container for aerosol and preparation thereof
EP0320510B1 (de) * 1987-06-26 1993-12-08 Winfried Jean Werding Vorrichtung zur lagerung und kontrollierten abgabe von unter druck stehenden produkten und verfahren zu ihrer herstellung
DE8709978U1 (de) * 1987-07-21 1987-10-08 A. u. K. Müller GmbH & Co KG, 4000 Düsseldorf Elektromagnetventil, insbesondere Auslaufventil für Brühwasser
GB8724243D0 (en) * 1987-10-15 1987-11-18 Metal Box Plc Laminates of polyolefin-based film
GB8724242D0 (en) * 1987-10-15 1987-11-18 Metal Box Plc Laminated metal sheet
IT1223451B (it) * 1987-11-24 1990-09-19 Coster Tecnologie Speciali Spa Procedimento per ottenere fondelli metallici protetti per valvole per aerosol e simili
GB2214891A (en) 1988-02-05 1989-09-13 Fibrenyle Ltd Containers for pressurized material
JP2562343B2 (ja) * 1988-02-23 1996-12-11 北海製罐株式会社 エアゾール容器及びエアゾール製品
EP0338670B1 (en) * 1988-03-22 1994-05-11 FISONS plc Pharmaceutical Compositions
IL89713A0 (en) * 1988-03-29 1989-09-28 Ciba Geigy Ag Novel alkanophenones
JPH0289633A (ja) * 1988-05-20 1990-03-29 Sumitomo Electric Ind Ltd フッ素樹脂被覆物
US4961966A (en) * 1988-05-25 1990-10-09 The United States Of America As Represented By The Administrator Of The Environmental Protection Agency Fluorocarbon coating method
US4902318A (en) * 1988-05-25 1990-02-20 The United States Of America As Represented By The Administrator Of The Environmental Protection Agency Inlet apparatus for gas-aerosol sampling
JPH0267374A (ja) * 1988-08-31 1990-03-07 Takeuchi Press Ind Co Ltd エアゾール缶容器
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8903629D0 (en) * 1989-02-17 1989-04-05 Metal Box Plc Metal/polymer laminates
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5006383A (en) * 1989-06-28 1991-04-09 The Dow Chemical Company Polymeric blend and laminated structures prepared therefrom
FR2650219B1 (fr) * 1989-07-06 1991-10-04 Pechiney Rhenalu Procede d'obtention de materiaux multicouches aptes a etre transformes par emboutissage ou emboutissage-etirage en corps creux
FR2649359B1 (fr) * 1989-07-06 1993-02-12 Cebal Bande ou portion de bande pour emboutissage ou emboutissage-etirage, et son utilisation
JP2600387B2 (ja) * 1989-09-06 1997-04-16 東洋紡績株式会社 金属貼合せ用ポリエステルフィルム
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5345980A (en) 1989-09-21 1994-09-13 Glaxo Group Limited Method and apparatus an aerosol container
US5043191A (en) * 1990-02-27 1991-08-27 Miles Inc. Method of protecting hard surfaces
DE4009397A1 (de) * 1990-03-23 1991-09-26 Weidenhammer Packungen Dosenartige verpackung fuer fliessfaehige produkte
AU614234B1 (en) * 1990-06-28 1991-08-22 Kabushiki Gaisha Tokai Vessel for aerosol
DE4023909A1 (de) * 1990-07-27 1992-01-30 Wild Rudolf Gmbh & Co Wiederverwendbarer behaelter aus kunststoff sowie seine herstellung und verwendung
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
DE69132258D1 (de) * 1990-11-14 2000-07-27 Titeflex Corp Laminate aus Fluorpolymer und Aluminium
ES2076022T3 (es) * 1990-12-12 1995-10-16 Du Pont Un sistema de recubrimiento no pegajoso con ptfe de diferentes viscosidades para obtener un gradiente de concentracion.
US5168107A (en) * 1990-12-12 1992-12-01 E. I. Du Pont De Nemours And Company Non-stick coating system with PTFE of two low melt viscosities for concentration gradient
JPH07108385B2 (ja) * 1990-12-12 1995-11-22 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 濃度勾配のためのｐｔｆｅとｐｆａ又はｆｅｐを有する非粘着性コーティング系
GB9027234D0 (en) * 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
EP0499142A3 (en) * 1991-02-09 1993-05-05 Hoechst Aktiengesellschaft Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
RU2027448C1 (ru) 1991-04-25 1995-01-27 Государственное предприятие "ВЭЛТ" Ингалятор
DE69227189T2 (de) * 1991-05-21 1999-02-25 Abbott Laboratories, Abbott Park, Ill. Aerosolinhalationsvorrichtung
RU2008939C1 (ru) 1991-06-10 1994-03-15 Вячеслав Николаевич Поздняков Физиотерапевтический ингалятор
RU2012362C1 (ru) 1991-06-24 1994-05-15 Юрий Алексеевич Волгин Ингалятор
DE4124730C3 (de) * 1991-07-25 2001-09-06 Ahc Oberflaechentechnik Gmbh Anodisierte Gegenstände aus Aluminium oder Magnesium mit in die Oxidschicht eingelagerten Fluorpolymeren und Verfahren zu deren Herstellung
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
DE69334088T2 (de) * 1992-06-25 2007-06-21 Denso Corp., Kariya System zum Identifizieren beweglicher Objekte
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
JP3303408B2 (ja) * 1992-07-09 2002-07-22 ダイキン工業株式会社 含フッ素樹脂複合微粒子
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5421492A (en) * 1993-11-02 1995-06-06 Glaxo Inc. Metered aerosol dispensing apparatus and method of use thereof
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5597433A (en) * 1994-05-27 1997-01-28 Panoramic, Inc. Method and apparatus for manufacturing plastic canisters
WO1996032099A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
CN1186473A (zh) * 1995-04-14 1998-07-01 葛兰素惠尔康公司 二丙酸氯地米松计定剂量吸入器
EA000892B1 (ru) * 1995-04-14 2000-06-26 Глаксо Веллкам Инк. Дозирующий ингалятор для салметерола
DK0820322T3 (da) * 1995-04-14 2002-10-07 Smithkline Beecham Corp Dosisudmålende inhalator til Fluticason Propionat
US5674592A (en) * 1995-05-04 1997-10-07 Minnesota Mining And Manufacturing Company Functionalized nanostructured films
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
JP3199699B2 (ja) 1999-04-14 2001-08-20 核燃料サイクル開発機構 弁座面の平坦度測定装置

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330391C (zh) * 2000-05-23 2007-08-08 葛兰素集团有限公司 供沙美特罗昔萘酸酯制剂用的气雾剂容器
CN102366406A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的沙美特罗替卡松气雾剂制剂
CN102366406B (zh) * 2011-10-21 2013-10-09 江苏长风药业有限公司 以氢氟烷烃为抛射剂的沙美特罗替卡松气雾剂制剂
CN106619658A (zh) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 一种医用气溶胶制剂及定量吸入气雾剂
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂

Also Published As

Publication number Publication date
EP0820323B1 (en) 2003-09-24
PT820323E (pt) 2004-03-31
DE69634865D1 (de) 2005-07-21
EP1547636A1 (en) 2005-06-29
DK0820323T3 (da) 2003-11-24
BR9604977A (pt) 1998-06-09
OA10626A (en) 2001-04-24
SK138997A3 (en) 1998-04-08
AU5481196A (en) 1996-10-30
EE04005B1 (et) 2003-04-15
JPH11509434A (ja) 1999-08-24
EP0820323A1 (en) 1998-01-28
RO119116B1 (ro) 2004-04-30
KR19980703848A (ko) 1998-12-05
ES2206572T3 (es) 2004-05-16
EP1366777A1 (en) 2003-12-03
PL322771A1 (en) 1998-02-16
NO974736D0 (no) 1997-10-13
BG64117B1 (bg) 2004-01-30
DE69630111D1 (de) 2003-10-30
CN1142798C (zh) 2004-03-24
NO974736L (no) 1997-12-11
ATE250439T1 (de) 2003-10-15
UA54386C2 (uk) 2003-03-17
HUP9802391A2 (hu) 1999-02-01
EA199700233A1 (ru) 1998-02-26
EP1908488A3 (en) 2008-04-16
MX9707864A (es) 1997-11-29
US6524555B1 (en) 2003-02-25
IS4579A (is) 1997-09-06
PL180901B1 (pl) 2001-04-30
NZ306280A (en) 1999-07-29
CZ296209B6 (cs) 2006-02-15
EP1366777B1 (en) 2005-06-15
HK1009405A1 (en) 1999-09-17
SK284447B6 (sk) 2005-04-01
EP1908488A2 (en) 2008-04-09
EA000892B1 (ru) 2000-06-26
KR100403899B1 (ko) 2004-03-20
CA2217954A1 (en) 1996-10-17
CA2217954C (en) 2005-02-15
ATE297773T1 (de) 2005-07-15
AU718263B2 (en) 2000-04-13
EE9700374A (et) 1998-06-15
TR199701169T1 (xx) 1998-03-21
AP979A (en) 2001-06-28
HUP9802391A3 (en) 2000-06-28
CZ326097A3 (cs) 1998-02-18
BG102022A (en) 1998-07-31
US6143277A (en) 2000-11-07
WO1996032150A1 (en) 1996-10-17
AP9701113A0 (en) 1997-10-31
CY2479B1 (en) 2005-06-03
DE69630111T2 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
CN1142798C (zh) 沙美特罗的计定剂量吸入器
CN1113675C (zh) 丙酸福地卡松的计定剂量吸入器
CN1217654C (zh) 舒喘宁的计定剂量吸入器
CN1186473A (zh) 二丙酸氯地米松计定剂量吸入器
US20030183223A1 (en) Metered dose inhaler
JP2004509031A (ja) フルオロカーボンポリマーで２回以上コーティングした定量式吸入缶
US20040223919A1 (en) Metered dose inhaler having internal surfaces coated with fluorocarbon polymer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SMITHKLINE BEECHAM CORP.

Free format text: FORMER OWNER: GLAXO INC.

Effective date: 20040423

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20040423

Address after: American Pennsylvania

Patentee after: Smithkline Beechan Corp.

Address before: North Carolina

Patentee before: Glaxo Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1046536

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20040324

EXPY Termination of patent right or utility model